Pharmacological Studies for Developing Si-Jun-Zi-Tang Extract as an Adjuvant of Temozolomide in Treating Glioblastoma

Temozolomide (TMZ) is the sole first-line drug for treating glioblastoma. However, it has toxicities. Our preliminary studies suggest that Si-Jun-Zi-Tang extract (SJZT) enhances the anti-glioblastoma effects and reduces the toxicities of TMZ. Under this project, we will further study the anti-glioblastoma effects of SJZT in combination with TMZ (SJZT-plus-TMZ), and investigate the mechanisms by which SJZT enhances the anti-glioblastoma effects of TMZ in cell and mouse models. We will also assess the safety of SJZT-plus-TMZ in tumor-bearing mice. Successful completion of this project will facilitate the development of SJZT as an adjuvant of TMZ for treating glioblastoma.